Apr 03, 2018 7:00am EDT Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy
Mar 06, 2018 4:01pm EST Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
Mar 01, 2018 7:30am EST Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
Feb 27, 2018 7:30am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results
Feb 16, 2018 5:15pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Jan 26, 2018 4:05pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Jan 05, 2018 4:05pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Jan 04, 2018 7:30am EST Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
